Overview Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus Status: Active, not recruiting Trial end date: 2021-12-13 Target enrollment: Participant gender: Summary The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab. Phase: Phase 3 Details Lead Sponsor: AstraZenecaCollaborator: PRA Health Sciences